JavaScript is currently not supported/disabled by this browser. Please enable JavaScript for full functionality.

Call Us 1 - 866 - 986 - 9598
[email protected]

Sign Up

Login
- My Order
- Return Requests
- Track my Order

Home / Cells / Cell Lines

SLAMF7 (CS1) CHO Recombinant Cell Line (Low Expression)

SKU : BHC18200298

Contact us to order

Tel

+1 866.986.9598

Email

[email protected]

Get a Quote

Request More Infos

BPS Bioscience

view supplier details

Order Now

Credit card payments now incur a 3% fee.

Contact us to order

Tel

+1 866.986.9598

Email

[email protected]

Get a Quote

Ask Merchant

Request More Infos

Sample Request

Mfr.No.	79608-L
Description	Recombinant clonal stable CHO cell line constitutively expressing full length human SLAMF7 protein, also known as CS1 or CD319 (Genbank #NM_021181). Surface expression of SLAMF7 was confirmed by flow cytometry. Each stable clonal cell line was selected for different levels of SLAMF7 [removed]High, Medium, Low) to mimic different stages of cancer target cells with various SLAMF7 expression levels. Mycoplasma testing: This cell line has been screened using the MycoAlert Mycoplasma Detection Kit (Lonza, #LT07-118) to confirm the absence of Mycoplasma contamination. MycoAlert Assay Control Set (Lonza, #LT07-518) was used as a positive control. Host Species: hamster Supplied as Each vial contains ~ 2 x 10^6 cells in 1 ml of 10% DMSO in FBS.
Background	The surface antigen SLAMF7 is expressed on a fraction of normal lymphocytes, including subsets of natural killer (NK) cells, T cells, and B cells. It is a robust marker of normal plasma cells and malignant plasma cells in multiple myeloma. In contrast to CD138 (the traditional plasma cell marker), CD319/SLAMF7 is much more stable and allows robust isolation of malignant plasma cells from patient samples. SLAMF7 is under intense investigation as a target for immunotherapy in multiple myeloma. It has been demonstrated that SLAMF7-CAR T cells prepared from patients and healthy donors confer potent antimyeloma reactivity. SLAMF7-CAR T cells confer fratricide of SLAMF7+/high normal lymphocytes. SLAMF7-CAR T cells represent a novel therapeutic agent for the treatment of patients with SLAMF7-expressing multiple myeloma malignancies.
Application	Useful as SLAMF7-expressing target cells in co-culture assay with SLAMF7-CAR T cells, for both SLAMF7-specific cell killing assay and cytokine production assay.
Host Cell	CHO
Species	Human
Synonyms	CS1, CD319
Shipping Temperature	-80°C (dry ice)
Note	LICENSE DISCLOSURE: Purchase of this cell line grants you with a 10-year license to use this cell line in your immediate laboratory, for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make the cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit the use of this cell line in humans or for therapeutic or drug use. The license does not permit modification of the cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license and result in an immediate cease of sales and distribution of Biohippo products to your laboratory. Biohippo does not warrant the suitability of the cell line for any particular use, and does not accept any liability in connection with the handling or use of the cell line. Modifications of this cell line, transfer to another facility, or commercial use of the cells may require a separate license and additional fees; contact [email protected] for details. Publications using this cell line should reference Biohippo Inc. Warning: Avoid freeze/thaw cycles.

Storage Stability	Store in liquid nitrogen immediately upon receipt.

Reference	1. Kramer, B. Role of the NK cell-activating receptor CRACC in periodontitis. Infect. Immun. 81 (3), 690-696 (2013) 2. Boles, K.S., et al. Molecular cloning of CS1, a novel human natural killer cell receptor belonging to the CD2 subset of the immunoglobulin superfamily. Immunogenetics 52 (3-4), 302-307 (2001)3. Gogishvili, T., et al. SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes. Blood 130:2838-2847 (2017)

Product Manual	Datasheet

Have you used this product?

Rate it now..!!

Login to Review

SKU	Supplier No.	Size	Your price	Quantity
BHC18200298	79608-L	2 vials	$7507.50		Add to Cart

ebiohippo.com provides biomedical researchers with a one-stop informatic shopping experience by transforming biotechnology products’ data into a ready-to-analyze state. We collect and unify suppliers’ data on a single platform to reduce the time of searching, uncertainty, and cost of scientific experiments.

© 2024 Biohippo. All rights reserved.